Skin
Androgenetic Alopecia
Androgenetic Alopecia is a skin condition involving hair loss and changes in hair growth or hair health. It describes the hair-related condition itself, not a single product or treatment.
Start with a focused overview of Androgenetic Alopecia and its place among skin conditions.
This list shows research findings, not treatments. Nothing here replaces medical care. If you have this condition, talk to a doctor.
What may help
What studies found for each option, best evidence first.
1 option:1 some evidence
Red Light Therapy (Photobiomodulation)practiceSome evidence it helpsSize of effect: Not known
Some human studies found a benefit. More research could change this.
All 2 studies with a clear result found a benefit.
A 2025 systematic review pooling randomized trials found increased hair density. A 2021 review also reported increased hair count and density compared with sham.
Open the Red Light Therapy (Photobiomodulation) page
The expert view shows every study, dose protocol and source.
What may help
Interventions recorded as helping with this condition1 listedMost likely to help, from the evidence we have
- →PracticesRed Light Therapy (Photobiomodulation)CertaintyMediumSourceRCT
A 2025 systematic review pooling randomized trials found increased hair density (eSMD 1.32, 95% CI 1.00 to 1.63). A 2021 review also reported increased hair count and density compared with sham.
Who was studied
- People with a condition
- Alopecia Androgenetic
- Carpal Tunnel
- Fibromyalgia
- Fracture
- Mild Cognitive Impairment
- Neck Pain
- +6 more
Open Red Light Therapy (Photobiomodulation)Study result
Moderate certainty for increased hair density (eSMD 1.32, 95% CI 1.00 to 1.63)
What to avoid
Interventions recorded as making it worseNothing in this library is currently recorded as making Androgenetic Alopecia worse. Coverage is partial, and absence here is not evidence of safety.
How to read the evidence
Evidence tier — overall strength of the evidence for the whole compound
- StrongWell established — backed by strong, consistent human research.
- ModerateSome genuine support, but mostly from small or lower-quality studies. Promising, not proven.
- PreliminaryEarly-stage evidence — a promising hypothesis, not an established effect yet.
- LimitedVery limited evidence — treat this as a hypothesis, not proof.
- InsufficientNot enough good evidence to draw conclusions yet.
Certainty — how sure we can be that the effect is real
- Very highVery sure — strong, consistent evidence
- HighFairly sure — consistent evidence from good studies
- MediumModerately sure — new studies could change this
- LowNot sure — little or mixed evidence
- Very lowVery unsure — almost no usable evidence
Source — where the data comes from
- Meta-analysisPooled analysis of many trials — the strongest evidence
- RCTRandomized controlled trial — a strong human study design
- ClinicalA human clinical study
- Reference knowledgeFrom general health-science or pharmacology references, not a study of this exact claim
- Animal researchStudied in animals, not humans
- Community reportsAggregated user reports — anecdotal signal, not evidence
- TheoreticalMechanism-based reasoning, not yet tested
Study grade — quality of each underlying study (A best, D weakest)
- AHigh-quality — strong, consistent human trials
- BGood — solid evidence with some limitations
- CModerate — limited, small, or mixed-quality studies
- DWeak — preliminary, indirect, or animal-only
Confidence — how strongly the sources back a finding
A 0–100 score from study quality and agreement
Most supplement evidence is graded C–D. Read it as preliminary signal, not proof.
Full write-up
What is it
Androgenetic Alopecia is a skin condition involving hair loss and changes in hair growth or hair health. It describes the hair-related condition itself, not a single product or treatment. Ashwagandha and Astragalus are examples of options studied in relation to this outcome, with findings that should be considered alongside the evidence information for each option.
Evidence-backed options
Ashwagandha was studied as a topical root-extract serum applied daily. In the available study, hair growth and hair-health measures improved after 75 days, providing a defined treatment period and assessment point. This does not establish how quickly changes began or whether the findings apply to every form of Ashwagandha or every person with androgenetic alopecia.
Astragalus is represented by Astragaloside IV, which has been described in relation to impeding the Fas/Fas ligand-mediated apoptotic pathway and as a promising alternative approach for hair loss. However, the available description does not specify a topical or oral regimen, dose, treatment duration, time to effect, or measured clinical hair outcome. Overall, the options have limited support, and the information is more clinically specific for Ashwagandha than for Astragalus. These findings are educational and do not determine whether either option is appropriate for an individual; medical conditions should be discussed with a clinician.